<DOC>
	<DOCNO>NCT03050619</DOCNO>
	<brief_summary>Empagliflozin , sodium glucose cotransporter 2 ( SGLT-2 ) inhibitor , launch United Kingdom ( UK ) August 2014 . It expect patient initiate empagliflozin may differ characteristic patient initiate glucose lower drug ( GLDs ) market longer ( e.g . patient may poorer glucose control ) . Therefore , propose study aim characterize patient T2DM UK initiate empagliflozin term baseline characteristic , concomitant medication , comorbidities compare patient type 2 diabetes mellitus ( T2DM ) initiate SGLT-2 inhibitor non-insulin GLDs . Due mode action , patient take empagliflozin experience weight loss clinical trial . A theoretical possibility exist empagliflozin may use patient without T2DM . Therefore , study also aim assess potential off-label use empagliflozin compare non-insulin GLDs .</brief_summary>
	<brief_title>Characteristics Empagliflozin Initiators</brief_title>
	<detailed_description>Study Design : cross sectional</detailed_description>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criterion : All patient require meet follow criterion : At least 12 month continuous registration prior index date practice contribute standard ( UTS ) data Clinical Practice Research Datalink ( CPRD ) . Infants young 1 year require 12 month continuous UTS registration CPRD . A new user one index prescription ( empagliflozin , SGLT2 inhibitor , noninsulin GLDs ) fix dose combination ( FDC ) metformin . Exclusion criterion : There exclusion criterion study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>